Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study

(2015) Sanjoy K Paul et al.   Cardiovascular Diabetology

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

(2015) Rafael Simó et al.   Cardiovascular Diabetology

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

(2015) Keiichi Torimoto et al.   Cardiovascular Diabetology

Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective

(2015) Boaz Hirshberg et al.   Current Diabetes Reports

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

(2015) Francesco Giorgino et al.   DIABETES CARE

Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials

(2015) S. R. K. Seshasai et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

(2015) R. S. Weinstock et al.   DIABETES OBESITY & METABOLISM

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

(2015) Lawrence Blonde et al.   LANCET

Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes

(2015) Rodney A. Hayward et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis

(2015) Miles Fisher et al.   Lancet Diabetes & Endocrinology

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

(2015) Tara Gurung et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

(2015) Hiroshi Nomoto et al.   PLoS One

Cardiovascular Actions of Incretin-Based Therapies

(2014) John R. Ussher et al.   CIRCULATION RESEARCH

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

(2014) Guillermo Umpierrez et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

(2014) Z. Skrivanek et al.   DIABETES OBESITY & METABOLISM

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

(2014) Yasuo Terauchi et al.   ENDOCRINE JOURNAL

Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

(2014) Keith C. Ferdinand et al.   HYPERTENSION

Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes

(2014) Louis Kuritzky et al.   POSTGRADUATE MEDICINE

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

(2012) Michael E Cobble et al.   Cardiovascular Diabetology

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

(2012) G. Grunberger et al.   DIABETIC MEDICINE

Cardiovascular Effects of Glucagonlike peptide–1 Agonists

(2011) Michael H. Davidson   AMERICAN JOURNAL OF CARDIOLOGY

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

(2011) Robert Ratner et al.   Cardiovascular Diabetology

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

(2011) Steven P Marso et al.   Diabetes & Vascular Disease Research

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

(2011) G. E. Umpierrez et al.   DIABETES OBESITY & METABOLISM

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control

(2010) P. Anagnostis et al.   DIABETES OBESITY & METABOLISM

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Intensive glucose control and macrovascular outcomes in type 2 diabetes

(2009) F. M. Turnbull et al.   DIABETOLOGIA

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE